Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1%

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR - Get Free Report) were down 3.1% during mid-day trading on Wednesday . The company traded as low as $0.64 and last traded at $0.66. Approximately 1,675,141 shares traded hands during trading, an increase of 93% from the average daily volume of 867,677 shares. The stock had previously closed at $0.68.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a report on Wednesday, February 14th.

Citius Pharmaceuticals Trading Down 3.1 %

The firm has a market cap of $105.53 million, a PE ratio of -2.55 and a beta of 1.54. The stock has a fifty day simple moving average of $0.78 and a two-hundred day simple moving average of $0.76.

Citius Pharmaceuticals (NASDAQ:CTXR - Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.19). As a group, sell-side analysts predict that Citius Pharmaceuticals, Inc. will post -0.21 earnings per share for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

Large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of Citius Pharmaceuticals during the 3rd quarter worth $39,000. Allspring Global Investments Holdings LLC bought a new stake in Citius Pharmaceuticals during the third quarter worth about $76,000. Wealth Advisory Solutions LLC purchased a new position in shares of Citius Pharmaceuticals in the 1st quarter worth about $135,000. Finally, BNP Paribas Financial Markets increased its position in shares of Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company's stock valued at $62,000 after purchasing an additional 32,686 shares during the last quarter. Institutional investors own 16.88% of the company's stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.